# EDGAR Filing Document

**Accession Number:** 0001402328
**File Stem:** 0001683168-26-003259
**Filing Date:** 2026-4
**Character Count:** 128810
**Document Hash:** 5f805e21507c341aaa485b1c88236968
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-003259.hdr.sgml**: 20260512

**ACCESSION NUMBER**: 0001683168-26-003259

**CONFORMED SUBMISSION TYPE**: DRS

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sunshine Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001402328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 205566275
- **STATE OF INCORPORATION:** CO
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DRS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 377-09306
- **FILM NUMBER:** 26906490

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAS OLAS WAY
- **STREET 2:** CU4 SUITE 433
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-330-0684

**MAIL ADDRESS:**
- **STREET 1:** 333 LAS OLAS WAY
- **STREET 2:** CU4 SUITE 433
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sunshine Biopharma, Inc
- **DATE OF NAME CHANGE:** 20091102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Mountain West Business Solutions, Inc
- **DATE OF NAME CHANGE:** 20071030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** mountain west business solutions,inc
- **DATE OF NAME CHANGE:** 20070607

As submitted to the Securities and Exchange Commission on April 28, 2026. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-1**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

---

| |
|:---|
| **SUNSHINE BIOPHARMA INC.** |
| (Exact name of registrant as specified in its charter) |

---

<u>Colorado</u> <u>8731</u> <u>20-5566275</u> <br> (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.)

333 Las Olas Way, CU4 Suite 433

Fort Lauderdale, FL 33301

<u>(954) 330-0684</u>

(Address, including zip code, and telephone number,

including area code, of registrant's principal executive offices)

Dr. Steve N. Slilaty

333 Las Olas Way, CU4 Suite 433

Fort Lauderdale, FL 33301

<u>(954) 330-0684</u>

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

*Copies to:*

---

| | |
|:---|:---|
| Gregory Sichenzia, Esq.<br> Jeff Cahlon, Esq.<br> Sichenzia Ross Ference Carmel LLP<br> 1185 Avenue of the Americas<br> New York, New York 10036 <br> Tel: (212) 930-9700 | Anthony W. Basch, Esq.<br> J. Britton Williston, Esq.<br> Shannon M. McDonough, Esq.<br> Kaufman & Canoles, P.C.<br> 1021 E. Cary St., Suite 1400<br> Richmond, Virginia 23219<br> Tel: (804) 771-5700 |

---

**As soon as practicable after the effective date of this registration statement**

(Approximate date of commencement of proposed sale to the public)

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.**

**The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.** 

---

| | | |
|:---|:---|:---|
| **PRELIMINARY PROSPECTUS** | **SUBJECT TO COMPLETION** | **DATED APRIL __, 2026** |

---

![](logo.jpg)

$6,000,000

Up to Common Units

Each Common Unit Consisting of One Share of Common Stock and Two Series C Warrants

Up to Pre-Funded Units

Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock and Two Series C Warrants

Up to Shares of Common Stock Included in the Common Units

Up to Pre-Funded Warrants Included in the Pre-Funded Units

Up to Series C Warrants Included in the Common Units and Pre-Funded Units

Up to Shares of Common Stock underlying the Pre-Funded Warrants

Up to Shares of Common Stock underlying the Series C Warrants

Sunshine Biopharma Inc. is offering, on a best efforts basis, up to common units (the "Common Units"), each Common Unit consisting of one share of our common stock, par value $0.001 per share, and two Series C Warrants, each Series C Warrant exercisable for one share of common stock.

The Series C Warrants will have an initial exercise price of $___ per share (equal to 100% of the public offering price per Common Unit), subject to adjustment, and will be exercisable for a period of five years commencing upon issuance. See "[Description of Capital Stock—Series C Warrants Offered in this Offering](#s1_019)."

We are also offering to certain purchasers whose purchase of Common Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding shares of common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded units (the "Pre-Funded Units"), each Pre-Funded Unit consisting of one pre-funded warrant to purchase one share of common stock (the "Pre-Funded Warrants"), and two Series C Warrants. The purchase price of each Pre-Funded Unit will be equal to the price per Common Unit, minus $0.001, and the exercise price of each Pre-Funded Warrant will be $0.001 per share. The Pre-Funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. For each Pre-Funded Unit we sell, the number of Common Units we are offering will decrease on a one-for-one basis.

This offering also relates to the shares of common stock issuable upon the exercise of the Pre-Funded Warrants and the Series C Warrants.

The Common Units and Pre-Funded Units will have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of common stock or Pre-Funded Warrants and the Series C Warrants comprising the Common Units or the Pre-Funded Units, as applicable, are immediately separable and will be issued separately in this offering.

We have assumed a public offering price of $ per Common Unit (or $____ per Pre-Funded Unit), based on the last reported sale price of our common stock on , 2026. The actual public offering price will be determined between us, Aegis Capital Corp. (whom we refer to herein as "Aegis" or the "placement agent") and the investors in the offering, and may be at a discount to the current market price of our common stock. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price.

Our common stock is listed on The Nasdaq Capital Market ("Nasdaq"), under the symbol "SBFM." On April 27, 2026, the last reported sale price of our common stock was $0.99 per share. We do not intend to apply for a listing of the Common Units, the Pre-Funded Units, the Pre-Funded Warrants, or the Series C Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants and the Series C Warrants will be limited.

The Common Units and Pre-Funded Units will be offered at a fixed price and are expected to be issued in a single closing. There is no minimum number of securities or minimum aggregate amount of proceeds for this offering to close. However, notwithstanding the foregoing, the shares of our common stock underlying the Pre-Funded Warrants and the Series C Warrants will be offered on a continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended (the "Securities Act"). We expect this offering to be completed not later than one business day following the commencement of sales in this offering (after the effective date of the registration statement of which this prospectus forms a part) and we will deliver all securities to be issued in connection with this offering upon receipt of investor funds received by us. Accordingly, neither we nor the placement agent have made any arrangements to place investor funds in an escrow account or trust account.

We have engaged Aegis Capital Corp. to act as our exclusive placement agent in connection with this offering. The placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus. The placement agent is not purchasing or selling any of the securities we are offering and the placement agent is not required to arrange the purchase or sale of any specific number or dollar amount of securities. Because there is no minimum offering amount required as a condition to closing in this offering, the actual offering amount, placement agent's fees and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts described throughout this prospectus. We have agreed to pay the placement agent the placement agent fees set forth in the table below and to provide certain other compensation to the placement agent. See "[Plan of Distribution](#s1_010)" for more information regarding these arrangements.

**Investing in our securities involves a high degree of risk. See "[Risk Factors](#s1_004)" beginning on page 4 of this prospectus to read about factors you should consider before investing in our securities.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

---

| | | |
|:---|:---|:---|
|  | **Per Pre-Funded Unit** | **Total** |
| Public offering price | $— | $|
| Placement agent fees<sup>(1)</sup> | $— | $|
| Proceeds to us, before expenses | $— | $|

---

(1) Does not include a non-accountable expense allowance
 of 2.0% of the aggregate gross proceeds. We have also agreed to pay certain accountable expenses of the placement agent. See
 " [Plan of Distribution](#s1_010) " beginning on page 13 of this prospectus for additional information
 regarding compensation to be received by the placement agent.

Delivery of the securities is expected to be made on or about , 2026.

*Sole placement agent*

**Aegis Capital Corp.**

The date of this prospectus is , 2026

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [PROSPECTUS SUMMARY](#s1_002) | 1 |
| [THE OFFERING](#s1_003) | 2 |
| [RISK FACTORS](#s1_004) | 4 |
| [CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS](#s1_005) | 6 |
| [USE OF PROCEEDS](#s1_006) | 6 |
| [CAPITALIZATION](#s1_007) | 7 |
| [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#s1_008) | 8 |
| [DESCRIPTION OF CAPITAL STOCK](#s1_009) | 9 |
| [PLAN OF DISTRIBUTION](#s1_010) | 13 |
| [LEGAL MATTERS](#s1_011) | 16 |
| [EXPERTS](#s1_012) | 16 |
| [INFORMATION INCORPORATED BY REFERENCE](#s1_013) | 16 |
| [WHERE YOU CAN FIND MORE INFORMATION](#s1_014) | 17 |

---

You should rely only on the information contained in or incorporated by reference in this prospectus or in any free writing prospectus that we may provide to you in connection with this offering. Neither we nor the placement agent have authorized anyone to provide you with information different from, or in addition to, that contained in or incorporated by reference in this prospectus or any such free writing prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. We can provide no assurance as to the reliability of any other information that others may give you. Neither we nor the placement agent is making an offer to sell or seeking offers to buy these securities in any jurisdiction where or to any person to whom the offer or sale is not permitted. The information in this prospectus is accurate only as of the date on the front cover of this prospectus, and the information in any free writing prospectus that we may provide you in connection with this offering is accurate only as of the date of such free writing prospectus. Our business, financial condition, results of operations and prospects may have changed since those dates.

i

**PROSPECTUS SUMMARY**

*This summary highlights certain information about us and this offering contained elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our securities, you should read the entire prospectus and the information incorporated herein carefully, including "[Risk Factors](#s1_004)" on page 4, and the financial statements and related notes incorporated by reference in this prospectus.*

 

*As used in this prospectus and unless otherwise indicated, the terms "we," "us," "our," "Sunshine Biopharma," or the "Company" refer to Sunshine Biopharma Inc. and its wholly owned subsidiaries*.

**Overview**

We are a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. We have two wholly owned subsidiaries: (i) Nora Pharma Inc. ("Nora Pharma"), a Canadian corporation, through which we currently have 71 generic prescription drugs on the market in Canada, and (ii) Sunshine Biopharma Canada Inc. ("Sunshine Canada"), a Canadian corporation which develops and sells OTC supplements.

In addition, we are conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an LNP encapsulated mRNA targeted for liver cancer, and (ii) SBFM-PL4, a protease inhibitor for treatment of SARS Coronavirus infections.

**THE OFFERING**

---

| | |
|:---|:---|
| Common Units offered<br>| Up to Common Units, each Common Unit consisting of one share of common stock and two Series C Warrants. We are also registering the shares of our common stock issuable upon exercise of the Series C Warrants.<br>|
| Series C Warrants offered | The Series C Warrants will be exercisable immediately upon issuance at an initial exercise price of $____ (equal to 100% of the public offering per Common Unit.) and will expire five years from the date of issuance. If we effect any share split, share dividend, share combination, recapitalization or other similar transaction involving our common stock (a "Share Combination Event"), and the lowest volumed weighted average price of our common stock during the period commencing five consecutive trading days immediately preceding and ending five consecutive trading days immediately following the Share Combination Event is less than the then-effective exercise price of the Series C Warrants, then the exercise price will be reduced (but not increased) to such lowest volume weighted average price, subject to a minimum exercise price of $____ (50% of the initial exercise price), and the number of shares issuable upon exercise will increase so that the aggregate exercise price payable upon full exercise of the Series C Warrants after such adjustment equals the aggregate exercise price payable upon full exercise immediately prior to such adjustment. The Share Combination Event provision will be effective only upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (the "Warrant Stockholder Approval"). The Series C Warrants will be subject to no more than one such adjustment upon a Share Combination Event. See "[Description of Capital Stock—Series C Warrants Offered in this Offering](#s1_019)." |
| Pre-Funded Units we are offering | We are offering to those purchasers whose purchase of Common Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the closing of this offering, in lieu of purchasing Common Units, up to Pre-Funded Units, each Pre-Funded Unit consisting of one Pre-Funded Warrant and two Series C Warrants. Each Pre-Funded Warrant will be exercisable for one share of our common stock. The purchase price of each Pre-Funded Unit is equal to the public offering price per Common Unit, minus $0.001, and the exercise price of each Pre-Funded Warrant is $0.001 per share. The Pre-Funded Warrants will be exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. We are also registering the shares of common stock issuable upon exercise of the Pre-Funded Warrants. For each Pre-Funded Unit we sell, the number of Common Units we are offering will decrease on a one-for-one basis. See "[Description of Capital Stock—Pre-Funded Warrants Offered in this Offering](#s1_018)." |
| Common stock outstanding immediately before this offering | 5005945 |
| Common stock to be outstanding after this offering | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. |

---

---

| | |
|:---|:---|
| Use of proceeds | We estimate that the net proceeds to us from this offering will be approximately $ million, after deducting placement agent fees and estimated offering expenses.<br>We intend to use the net proceeds of this offering for general corporate purposes, including working capital. See "[Use of Proceeds](#s1_006)." |
| Risk factors | Investing in our securities involves a high degree of risk. See "[Risk Factors](#s1_004)" beginning on page 4 of this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. |
| Nasdaq symbol | Our common stock is listed on Nasdaq under the symbol "SBFM." |

---

(1) Based on assumed public offering price of $ per Common Unit, the closing price of our common stock on _________, 2026.

Unless otherwise indicated, all information contained in this prospectus assumes the sale of all of the Common Units offered hereby at an assumed public offering price of $ per Common Unit, no sale of any Pre-Funded Units, and no exercise of any Series C Warrants. The number of shares of our common stock that are and will be outstanding immediately before and after this offering as shown above is based on 5,005,945 shares outstanding as of April 24, 2026, and excludes, as of that date:

&nbsp;&nbsp;&nbsp;&nbsp;· 482 shares issuable upon exercise of outstanding warrants with an exercise price of $220;

&nbsp;&nbsp;&nbsp;&nbsp;· 400 shares issuable upon exercise of outstanding warrants with an exercise price of $4,000; and

&nbsp;&nbsp;&nbsp;&nbsp;· 15,227,962 shares issuable upon exercise of outstanding Series B Warrants with an exercise price of $2.07,
subject to adjustment.

**RISK FACTORS**

*An investment in our securities involves a high degree of risk. You should carefully consider the following risks and all of the other information contained or incorporated by reference in this prospectus before deciding whether to invest in our securities, including the risks and uncertainties described below and under the caption "Risk Factors" in our most recently filed Annual Report on Form 10-K, as these risk factors are amended or supplemented by subsequent reports we file with the SEC. Our business, financial condition, results of operations and future prospects may be adversely affected as a result of such risks. In such an event, the market price of our common stock could decline, and you could lose part or all of your investment.*

**Risks Relating to this Offering and Ownership of Our Securities**

***The Series C Warrants and Pre-Funded Warrants will not be listed or quoted on any exchange.***

There is no established public trading market for the Pre-Funded Warrants or Series C Warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the Pre-Funded Warrants or Series C Warrants on any national securities exchange or other nationally recognized trading system, including Nasdaq. Without an active market, the liquidity of the Pre-Funded Warrants and Series C Warrants will be limited.

***Except as otherwise provided in the Series C Warrants and Pre-Funded Warrants, holders of Series C Warrants and Pre-Funded Warrants purchased in this offering will have no rights as stockholders until such holders exercise their Series C Warrants or Pre-Funded Warrants and acquire our common stock.***

Except as otherwise provided in the Series C Warrants and Pre-Funded Warrants, until holders of Series C Warrants or Pre-Funded Warrants acquire our common stock upon exercise of the Series C Warrants or Pre-Funded Warrants, holders of Series C Warrants and Pre-Funded Warrants will have no rights with respect to our common stock underlying such Series C Warrants and Pre-Funded Warrants. Upon exercise of the Series C Warrants and Pre-Funded Warrants, the holders will be entitled to exercise the rights of a holder of our common stock only as to matters for which the record date occurs after the exercise date.

***The Series C Warrants are speculative in nature.***

The Series C Warrants represent the right to acquire shares of common stock at a fixed price, subject to adjustment. Specifically, commencing on the date of issuance, holders of the Series C Warrants may acquire the shares of common stock issuable upon exercise of such Series C Warrants at an initial exercise price of $___ per share, subject to adjustment (see "[Description of Capital Stock—Series C Warrants Offered in this Offering](#s1_019)"). There can be no assurance that the market price of the shares of common stock will ever equal or exceed the exercise price of the Series C Warrants, and consequently, whether it will ever be profitable for holders to exercise the Series C Warrants.

***This is a best efforts offering; no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business.***

The placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth in this prospectus. We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us. Thus, we may not raise the amount of capital we believe is required for our business and may need to raise additional funds, which may not be available or available on terms acceptable to us, or at all. Despite this, any proceeds from the sale of securities offered by us will be available for our immediate use, and because there is no escrow account and no minimum offering amount in this offering, investors could be in a position where they have invested in us, but we are unable to fulfill our objectives due to a lack of interest in this offering.

***Our management will have broad discretion over the use of the net proceeds from this offering.***

We currently intend to use the net proceeds from the sale of our securities under this offering for general corporate purposes, including working capital. We have not reserved or allocated specific amounts for any of these purposes and we cannot specify with certainty how we will use the net proceeds (see "Use of Proceeds"). Accordingly, our management will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. We may use the net proceeds for corporate purposes that do not increase our operating results or market value.

***Additional stock offerings in the future may dilute then-existing shareholders' percentage ownership of the Company.***

Given our plans and expectations that we will need additional capital, we anticipate that we will need to issue additional shares of common stock or securities convertible or exercisable for shares of common stock, including convertible preferred stock, convertible notes, stock options or warrants. The issuance of additional securities in the future will dilute the percentage ownership of then current stockholders.

***If we are unable to continue to meet the listing requirements of Nasdaq, our common stock will be delisted.***

Our common stock currently trades on Nasdaq, where it is subject to various listing requirements, including Nasdaq Rule 5500(a)(2), which requires that our common stock maintain a minimum bid price of at least $1.00 to maintain its listing on Nasdaq (the "Bid Price Rule").

Our common stock has recently traded at prices slightly above or below the $1.00 Nasdaq required minimum bid price requirement. In addition, though we have obtained stockholder approval to authorize the board of directors to implement a reverse stock split in its discretion, in a ratio of up to 1-for-10, there is no assurance that, even if we implement a reverse split, we will be able to maintain compliance with the Bid Price Rule or other applicable requirements for continued listing on Nasdaq. If we are unable to maintain compliance with Nasdaq listing requirements, we could be subject to suspension and delisting proceedings. A delisting of our common stock could negatively impact us by: (i) reducing the liquidity and market price of our common stock; (ii) reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; (iii) limiting our ability to use certain registration statements to offer and sell freely tradeable securities, thereby limiting our ability to access the public capital markets; and (iv) impairing our ability to provide equity incentives to our employees.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

All statements in this prospectus and the documents incorporated by reference that are not historical facts should be considered "Forward Looking Statements" within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Some of the forward-looking statements can be identified by the use of words such as "believe," "expect," "may," "estimates," "should," "seek," "approximately," "intend," "plan," "estimate," "project," "continue" or "anticipates" or similar expressions or words, or the negatives of those expressions or words. These statements may be made directly in this prospectus and they may also be incorporated by reference in this prospectus from other documents filed with the SEC, and include, but are not limited to, statements about future financial and operating results and performance, statements about our plans, objectives, expectations and intentions with respect to future operations, and other statements that are not historical facts. These forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. In addition, these forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Actual results may differ materially from the anticipated results discussed in these forward-looking statements.

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable laws or regulations.

**USE OF PROCEEDS**

We estimate that the net proceeds to us from this offering from the sale of the securities will be approximately $ million, after deducting the placement agent fees and estimated offering expenses.

We intend to use the net proceeds we receive from this offering for general corporate purposes, including working capital. Our management will have broad discretion in the application of the net proceeds.

As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. Accordingly, our management will have broad discretion in the timing and application of these proceeds.

**CAPITALIZATION**

The following table sets forth our cash, as well as our capitalization, as of December 31, 2025, as follows:

&nbsp;&nbsp;&nbsp;&nbsp;· on an actual basis; and

· on a pro forma as adjusted basis, giving effect to (i) our issuance of 100,000 shares of common stock to a director for services on April 14, 2026, and (ii) the assumed sale by us of Common Units in this offering (assuming no sale of any Pre-Funded Units) at an assumed public offering price of $ per Common Unit, after deducting the placement agent fees and other estimated offering expenses payable by us.

You should read this table in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations," and our financial statements for the year ended December 31, 2025, and the related notes thereto, included in our annual report on Form 10-K for the year ended December 31, 2025 and incorporated by reference in this prospectus.

---

| | | |
|:---|:---|:---|
|  | **Actual** | **Pro forma<br> as adjusted** |
| Cash and cash equivalents | $9123308 | $– |
| Total liabilities | $7040707 | $7040707 |
| Shareholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, 30,000,000 authorized shares; $0.10 par value: 130,000 shares of Series B Preferred Stock issued and outstanding | $13000 | $13000 |
| &nbsp;&nbsp;&nbsp;Common stock, 3,000,000,000 authorized shares; $0.001 par value; 4,905,945 shares issued and outstanding, actual, shares issued and outstanding, pro forma as adjusted | $4905 | $– |
| &nbsp;&nbsp;&nbsp;Capital paid in excess of par value | $98100990 | $– |
| &nbsp;&nbsp;&nbsp;Accumulated comprehensive income | $(65309) | $(65309) |
| &nbsp;&nbsp;&nbsp;Accumulated (deficit) | $(75015126) | $(75015126) |
| Total shareholders' equity | $23080460 | $– |

---

The number of shares to be outstanding immediately after giving effect to this offering as shown above is based on 4,905,945 shares outstanding as of December 31, 2025, and excludes, as of such date:

&nbsp;&nbsp;&nbsp;&nbsp;· 482 shares issuable upon exercise of outstanding warrants with an exercise price of $220;

&nbsp;&nbsp;&nbsp;&nbsp;· 400 shares issuable upon exercise of outstanding warrants with an exercise price of $4,000; and

&nbsp;&nbsp;&nbsp;&nbsp;· 15,227,962 shares issuable upon exercise of outstanding Series B Warrants with an exercise price of $2.07,
subject to adjustment.

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT**

The following table sets forth certain information regarding the ownership of common stock and Series B Preferred Stock as of April 24, 2026, by (i) each of our directors, (ii) each of our executive officers, (iii) all of our directors and executive officers as a group, and (iv) any person or group as those terms are used in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), believed by us to beneficially own more than 5% of our common stock. Unless otherwise indicated, all shares are owned directly and the indicated person has sole voting and investment power. The percentages listed are based upon 5,005,945 shares of common stock and 130,000 shares of Series B Preferred Stock issued and outstanding as of April 24, 2026. Each share of Series B Preferred Stock entitles the holder to 1,000 votes. Except as otherwise set forth below, the address of each person below is c/o Sunshine Biopharma Inc., 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Title of Class** | **Name** | **Number of Shares<br> Beneficially Owned**  | **Percentage of shares beneficially owned before offering** | **Percentage of shares beneficially owned after offering <sup>(2)</sup>** |
| Common  | Dr. Steve N. Slilaty \*\* | 1,911 common <sup>(1)</sup><br>| \* (common)  | \* (common)  |
| Series B Preferred |  | 130,000 Series B Preferred | 100% of Series B Preferred | 100% (Series B Preferred) |
| Common | Camille Sebaaly \*\* | 60 | \* | \* |
| Common | Dr. Andrew Keller \*\* | 0 | \* | \* |
| Common | David Natan \*\* | 100000 | 2.0% | \* |
| Common | Dr. Rabbi Kiderchah \*\* | 1 | \* | \* |
| Common | Michel Roy \*\* | 1 | \* | \* |
| Common <br>Series B Preferred | All officers and directors as a group (6 persons) | 101,973 common<br> 130,000 Series B Preferred | \* (common) <br>100% (Series B Preferred) | \* (common) <br>100% Series B Preferred |
| Common Stock | Intracoastal Capital LLC <sup>(3)</sup> | 555597 | 9.99% | [●]% |

---

\* Less than 1%.

\*\* Officer and/or director of the Company.

(1) Includes 1,850 shares of common stock owned by Malek Chamoun, the former president of Nora Pharma Inc., a wholly-owned subsidiary of the Company. Dr. Slilaty controls the voting of Mr. Chamoun's shares through a voting agreement between Mr. Chamoun and Dr. Slilaty dated October 20, 2022.

(2) Assumes the sale of Common Units at an assumed public offering price of $ per Common Unit in this offering.

(3) Represents shares of common stock issuable upon exercise of a warrant (the "Intracoastal Warrant") held by Intracoastal Capital LLC ("Intracoastal"), and all such shares represent beneficial ownership of approximately 9.99% of the common stock, based on (a) 5,005,945 shares of common stock outstanding, plus (b) 555,597 shares issuable upon exercise of the Intracoastal Warrant. Based on Schedule 13G filed with the SEC on May 23, 2025, such shares may be deemed beneficially owned by Intracoastal, Mitchell P. Kopin and Daniel B. Asher (the "Reporting Persons"). The foregoing excludes 1,870,912 shares of common stock issuable upon exercise of the Intracoastal Warrant because the Intracoastal Warrant contains a blocker provision under which the holder thereof does not have the right to exercise the Intracoastal Warrant to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the common stock. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,426,509 shares of common stock. The address of the stockholder is 245 Palm Trail, Delray Beach, Florida 33483.

**DESCRIPTION OF CAPITAL STOCK**

**General**

Our authorized capital stock consists of 3,000,000,000 shares of common stock, par value of $0.001 per share, and 30,000,000 shares of preferred stock, par value $0.10 per share. 1,000,000 shares of our preferred stock are designated as Series B Preferred Stock.

As of April 24, 2026, there were 5,005,945 shares of our common stock outstanding, which does not include:

&nbsp;&nbsp;&nbsp;&nbsp;· 482 shares issuable upon exercise of outstanding warrants with an exercise price of $220;

&nbsp;&nbsp;&nbsp;&nbsp;· 400 shares issuable upon exercise of outstanding warrants with an exercise price of $4,000; and

&nbsp;&nbsp;&nbsp;&nbsp;· 15,227,962 shares issuable upon exercise of outstanding Series B Warrants with an exercise price of $2.07,
subject to adjustment.

**Common Stock**

Holders of our common stock are entitled to one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting rights. Therefore, holders of a majority of the voting power of our stockholders for the election of directors can elect all of the directors. Holders of one-third of the voting power of the Company's stockholders, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders of a majority of the voting power of the Company's stockholders is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to the Company's certificate of incorporation.

Holders of our common stock are entitled to share in all dividends that the board of directors, in its discretion, declares from legally available funds. In the event of a liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The Company's common stock has no pre-emptive rights, no conversion rights and there are no withdrawal provisions applicable to the Company's common stock.

**Series B Warrants**

As of the date of this prospectus, there are 15,227,962 Series B Warrants outstanding at a current exercise price of $2.07, subject to further adjustment. The Series B Warrants are exercisable until five years from the issuance date of February 15, 2024.

The Series B Warrants are exercisable, at the option of each holder, any time a registration statement registering the issuance of the shares of common stock underlying the Series B Warrants under the Securities Act is effective and available for the issuance of such shares, by delivery of an exercise notice and payment in full for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common stock underlying the Series B Warrants under the Securities Act is not effective, the holder may exercise the Series B Warrants through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant.

Subject to certain exemptions, if we sell, enter into an agreement to sell, or grant any option to purchase, or sell, enter into an agreement to sell, or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any shares of common stock, at an effective price per share less than the exercise price of the Series B Warrants then in effect, the exercise price of the Series B Warrants will be reduced to such price, and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate exercise price will remain unchanged.

If at any time on or after the date of issuance there occurs any share split, share dividend, share combination, recapitalization or other similar transaction involving our common stock and the lowest daily volume weighted average price during the period commencing five consecutive trading days immediately preceding and the five consecutive trading days immediately following such event is less than the exercise price of the Series B Warrants then in effect, then the exercise price of the Series B Warrants would be reduced to the lowest daily volume weighted average price during such period and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate price will remain unchanged.

**Blank Check Preferred Stock**

Our articles of incorporation authorize the issuance of 30,000,000 shares of preferred stock, par value $0.10 per share, in one or more series, subject to any limitations prescribed by law, without further vote or action by the stockholders. Each such series of preferred stock shall have such number of shares, designations, preferences, voting powers, qualifications, and special or relative rights or privileges as shall be determined by our board of directors, which may include, among others, dividend rights, voting rights, liquidation preferences, conversion rights and preemptive rights.

**Series B Preferred Stock**

1,000,000 shares of our authorized preferred stock have been designated Series B Preferred Stock. 130,000 shares of Series B Preferred Stock are outstanding and held by our chief executive officer, Dr. Steve N. Slilaty.

The Series B Preferred Stock votes together with the common stock on all matters submitted to a vote of the Company's stockholders. Each share of Series B Preferred Stock entitles the holder to 1,000 votes.

Upon any liquidation or dissolution of the Company, the Series B Preferred Stock will be entitled to a payment equal to the stated value of $0.10 per share, prior to any payments being made with respect to the common stock. The Series B Preferred Stock is not redeemable by the Company and is entitled to dividends when, as and if declared by the board of directors in its sole discretion.

**Pre-Funded Warrants to be issued in this offering**

The following summary of certain terms and provisions of the Pre-Funded Warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of, the Pre-Funded Warrants. Prospective investors should carefully review the terms and provisions of the form of Pre-Funded Warrant for a complete description of the terms and conditions of the Pre-Funded Warrants.

The term "pre-funded" refers to the fact that the purchase price of our common stock in this offering includes almost the entire exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.001. The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder, 9.99%) of our outstanding shares of common stock following the consummation of this offering the opportunity to make an investment in the Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of our common stock which would result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying the Pre-Funded Warrants at such nominal price at a later date.

*Duration*. The Pre-Funded Warrants offered hereby will entitle the holders thereof to purchase our shares of common stock at a nominal exercise price of $0.001 per share, commencing immediately on the date of issuance. There is no expiration date for the Pre-Funded Warrants.

*Exercise Limitation*. A holder will not have the right to exercise any portion of the Pre-Funded Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of our shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. However, any holder may increase or decrease such percentage (up to 9.99%), provided that any increase will not be effective until the 61st day after such election. It is the responsibility of the holder to determine whether any exercise would exceed the exercise limitation.

*Exercise Price*. The Pre-Funded Warrants will have an exercise price of $0.001 per share. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our shareholders.

*Transferability*. Subject to applicable laws, the Pre-Funded Warrants may be offered for sale, sold, transferred or assigned without our consent.

*Absence of Trading Market*. There is no established trading market for the Pre-Funded Warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Pre-Funded Warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited.

*Fundamental Transactions*. In the event of a fundamental transaction, generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation, merger, amalgamation or arrangement with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holder will have the right to receive, for each share of common stock that would have been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of the successor or acquiring corporation or of us if we are the surviving corporation, and any additional consideration receivable as a result of such fundamental transaction by a holder of the number of shares for which the pre-funded warrant was exercisable immediately prior to such fundamental transaction. The holders of the Pre-Funded Warrants may also require us to purchase the Pre-Funded Warrants from the holders by paying to each holder an amount equal to the Black Scholes value of the remaining unexercised portion of the Pre-Funded Warrants on the date of the fundamental transaction.

*No Rights as a Shareholder*. Except as otherwise provided in the Pre-Funded Warrants or by virtue of such holder's ownership of our shares of common stock, the holder of Pre-Funded Warrants does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the pre-funded warrant.

**Warrant Stockholder Approval**

Under Nasdaq listing rules, the Share Combination Event provision in the Series C Warrants will not be effective until, and unless, we obtain the approval of our stockholders. Our chief executive officer holds the majority of the voting power of our stockholders and we intend to promptly obtain such stockholder approval.

**Series C Warrants to be issued in this offering**

The following summary of certain terms and provisions of the Series C Warrants included in the Common Units and Pre-Funded Units hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of Series C Warrant which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Series C Warrant.

*Exercisability*. The Series C Warrants will be exercisable immediately upon issuance and at any time up to the date that is five years after their original issuance date. The Series C Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the Series C Warrants under the Securities Act is effective and available for the issuance of such shares, by payment in full for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common stock underlying the Series C Warrants under the Securities Act is not effective, the holder may elect to exercise the Series C Warrants through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant.

*Exercise Limitation*. A holder will not have the right to exercise any portion of the Series C Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Series C Warrants and Series B Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following notice from the holder to us.

*Exercise Price.* The initial exercise price per whole share of common stock purchasable upon exercise of the Series C Warrants is $________ (100% of the public offering price per Common Unit). The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.

*Share Combination Events*. Conditioned upon the receipt of the Warrant Stockholder Approval, if at any time on or after the date of issuance there occurs any share split, share dividend, share combination, recapitalization or other similar transaction involving our common stock and the lowest daily volume weighted average price during the period commencing five consecutive trading days immediately preceding and the five consecutive trading days immediately following such event is less than the exercise price of the Series C Warrants then in effect (a "Share Combination Event"), then the exercise price of the Series C Warrants will be reduced to the lowest daily volume weighted average price during such period (subject to a minimum exercise price of $____) (equal to 50% of the public offering price per Common Unit) and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate price will remain unchanged. The Series C Warrants will be subject to no more than one such adjustment upon a Share Combination Event.

*Transferability*. Subject to applicable laws, the Series C Warrants may be offered for sale, sold, transferred or assigned without our consent.

*Absence of Trading Market*. There is no established trading market for the Series C Warrants and we do not expect a market to develop. In addition, we do not intend to apply for the listing of the Series C Warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Series C Warrants will be limited.

*Fundamental Transactions*. In the event of a fundamental transaction, as described in the Series C Warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the Series C Warrants will be entitled to receive upon exercise of the Series C Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Series C Warrants immediately prior to such fundamental transaction. The holders of the Series C Warrants may also require us to purchase the Series C Warrants from the holders by paying to each holder an amount equal to the Black Scholes value of the remaining unexercised portion of the Series C Warrants on the date of the fundamental transaction.

*Rights as a Stockholder*. Except as otherwise provided in the Series C Warrants by virtue of such holder's ownership of shares of our common stock, the holder of a Series C Warrants does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Series C Warrant.

**PLAN OF DISTRIBUTION**

Aegis Capital Corp. ("Aegis" or the "placement agent") has agreed to act as our sole placement agent in connection with this offering subject to the terms and conditions of a placement agency agreement, dated , 2026 between Aegis and us. Aegis is not purchasing or selling any securities offered by this prospectus, nor is the placement agent required to arrange the purchase or sale of any specific number or dollar amount of the securities offered. The placement agent has agreed to use reasonable best efforts to arrange for the sale of all of the securities offered hereby. Therefore, we may not sell the entire amount of the securities offered pursuant to this prospectus. The placement agent may engage one or more sub-agents or selected dealers in connection with this offering.

In connection with the offering, we entered into a placement agency agreement with Aegis, which agreement includes representations and warranties by us. The public offering price of the securities in this offering has been determined based upon arm's-length negotiations between the purchasers and us. Our obligation to issue and sell the securities to the investors is subject to the closing conditions set forth in the placement agent agreement, including the absence of any material adverse change in our business and the receipt of certain opinions, letters and certificates from us or our counsel, which may be waived by the respective parties. All of the securities will be sold at the offering price specified in this prospectus and, we expect, at a single closing.

We will enter into a securities purchase agreement directly with certain investors, at the investor's option, who purchase our securities in this offering. Investors who do not enter into a securities purchase agreement will rely solely on this prospectus in connection with the purchase of our securities in this offering.

**Commissions and Expenses**

We have agreed to pay the placement agent an aggregate cash placement fee equal to seven percent (7.0%) of the gross proceeds in this offering. In addition, we have agreed to pay the placement agent a non-accountable expense allowance of two percent (2.0%) of the gross proceeds of the offering. We have also agreed to reimburse the placement agent for reasonable legal fees and disbursements incurred by the placement agent not to exceed an aggregate of $100,000. We estimate that the total expenses payable by us in connection with this offering, other than the placement agent fees referred to above, will be approximately $.

**Discretionary Accounts**

Aegis has informed us that it does not expect to make sales to accounts over which it exercises discretionary authority in excess of five percent (5%) of the securities being offered in this offering.

**Indemnification**

We have agreed to indemnify Aegis, its affiliates, and each person controlling Aegis against any losses, claims, damages, judgments, assessments, costs, and other liabilities, as the same are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of the offering, undertaken in good faith.

**Lock-Up Agreements**

Pursuant to certain "lock-up" agreements, our executive officers and directors have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling of any shares of common stock or securities convertible into or exchangeable or exercisable for any shares of common stock, whether currently owned or subsequently acquired, for a period of ninety (90) days after the closing date of the offering.

**Company Standstill**

We have agreed, for a period of ninety (90) days after the closing date of the offering, subject to certain exceptions, that we will not (a) offer, sell, issue, or otherwise transfer or dispose of, directly or indirectly, any equity of our Company or any securities convertible into or exercisable or exchangeable for equity of our Company; (b) file or caused to be filed any registration statement with the Commission relating to the offering of any equity of our Company or any securities convertible into or exercisable or exchangeable for equity of our Company; or (c) enter into any agreement or announce the intention to effect any of the actions described in subsections (a) or (b) hereof.

**Other Relationships**

The placement agent is a full service financial institution engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. The placement agent has in the past and may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates for which it has in the past and they may in the future receive customary fees. Without limiting the generality of the foregoing, the placement agent served as the underwriter for the public offerings we completed in February 2022 and February 2024, and as placement agent for the private placements we completed in March 2022, April 2022, May 2023 and April 2025, for which it received compensation.

In the ordinary course of its business activities, the placement agent and its affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively traded securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligation or otherwise) publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.

**Determination of Offering Price**

The public offering price of the securities we are offering was negotiated between us and the investors, in consultation with the placement agent based on the trading of our common stock prior to the offering, among other things. Other factors considered in determining the public offering price of the securities we are offering include our history and prospects, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.

**Regulation M**

The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by it and any profit realized on the resale of the securities sold by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required to comply with the requirements of the Securities Act and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including, without limitation, Rule 415(a)(4) under the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of shares of common stock by the placement agent acting as principal. Under these rules and regulations, the placement agent:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· may not engage in any stabilization activity in connection with our securities; and

· may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as
permitted under the Exchange Act, until it has completed its participation in the distribution.

**Potential Conflicts of Interest**

The placement agent and its affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which it may receive customary fees and reimbursement of expenses. In the ordinary course of its various business activities, the placement agent and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for its own accounts and for the accounts of its customers and such investment and securities activities may involve securities and/or instruments of our Company. The placement agent and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

**Electronic Distribution**

This prospectus may be made available in electronic format on websites or through other online services maintained by the placement agent or by an affiliate. Other than this prospectus, the information on the placement agent's website and any information contained in any other website maintained by the placement agent is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the placement agent, and should not be relied upon by investors.

**Offer Restrictions Outside the United States**

Other than in the United States, no action has been taken by us or the placement agent that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons who come into possession of this prospectus are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

**Transfer Agent and Registrar**

The transfer agent and registrar for our common stock is Equiniti Trust Company.

**Trading Market**

Our common stock is listed on the Nasdaq Capital Market under the symbol "SBFM." We do not intend to apply for listing of the Pre-funded Warrants or the Series C Warrants on any securities exchange or other nationally recognized trading system.

**LEGAL MATTERS**

We are being represented by Sichenzia Ross Ference Carmel LLP, New York, New York, with respect to certain legal matters as to United States federal securities and New York state law. The enforceability of the warrants will be passed upon for us by Sichenzia Ross Ference Carmel LLP, New York, New York. The validity of the securities offered hereby will be passed upon for us by Evans Case, LLP, Denver, CO. The placement agent is being represented by Kaufman & Canoles, P.C., Richmond, VA, in connection with this offering.

**EXPERTS**

The consolidated financial statements of Sunshine Biopharma Inc. as of and the year ended December 31, 2025 incorporated by reference in this prospectus have been audited by M&K CPA's, PLLC, independent registered public accounting firm, as set forth in their report thereon, appearing therein, and are incorporated by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. The consolidated financial statements of Sunshine Biopharma Inc. as of and for the year ended December 31, 2024, incorporated by reference in this prospectus have been audited by Bush & Associates CPA LLC, independent registered public accounting firm, as set forth in their report thereon, appearing therein, and are incorporated by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.

**INFORMATION INCORPORATED BY REFERENCE**

The SEC allows us to "incorporate by reference" into this prospectus information that we file with them. Incorporation by reference allows us to disclose important information to you by referring you to those other documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information.

This prospectus incorporates by reference the documents set forth below:

&nbsp;&nbsp;&nbsp;&nbsp;· our Annual Report on [Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/1402328/000168316826002644/sunshine_i10k-123125.htm) for the fiscal year ended December 31, 2025 filed with the SEC on April
3, 2026;

&nbsp;&nbsp;&nbsp;&nbsp;· our Current Reports on Form 8-K filed with the SEC on [February 5, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1402328/000168316826000789/sunshine_8k.htm) , [February 20, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1402328/000168316826001216/sunshine_8k.htm) , and [March 9, 2026](https://www.sec.gov/ix?doc=/Archives/edgar/data/1402328/000168316826001609/sunshine_8k.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;· the description of our common stock contained in our Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1402328/000168316822000830/sunshinebio_8a12b.htm) registering our
common stock under Section 12(b) under the Exchange Act, filed with the SEC on February 10, 2022; and

&nbsp;&nbsp;&nbsp;&nbsp;· all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d)
of the Exchange Act after the date of this prospectus and prior to the termination of this offering.

The information about us contained in this prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of any or all of these filings, at no cost, by writing or telephoning us at: Dr. Steve N. Slilaty, 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL 33301, telephone: (954) 330-0684.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the securities offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information about us and our securities offered hereby, we refer you to the registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address is http://www.sec.gov.

We are subject to the reporting requirements of the Exchange Act, and file annual, quarterly and current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, over the Internet at the SEC's website*.* We also maintain a website at https://sunshinebiopharma.com, at which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.

$6,000,000

Up to Common Units

Each Common Unit Consisting of One Share of Common Stock and Two Series C Warrants

Up to Pre-Funded Units

Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock and Two Series C Warrants

Up to Shares of Common Stock Included in the Common Units

Up to Pre-Funded Warrants Included in the Pre-Funded Units

Up to Series C Warrants Included in the Common Units and Pre-Funded Units

Up to Shares of Common Stock underlying the Pre-Funded Warrants

Up to Shares of Common Stock underlying the Series C Warrants

![](logo.jpg)

**Prospectus**

 

*Sole placement agent*

**Aegis Capital Corp.**

**, 2026**

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 13. Other Expenses of Issuance and Distribution.**

The following table sets forth all costs and expenses, other than the placement agent fees, expected to be incurred by us in connection with the sale of the securities being registered. All amounts shown are estimates except for the SEC registration fee and the FINRA filing fee.

---

| | |
|:---|:---|
|  | **Amount Paid** <br> **or to be Paid** |
| SEC registration fee | $\* |
| FINRA filing fee | $\* |
| Legal fees and expenses | $\* |
| Accounting fees and expenses | $\* |
| Miscellaneous fees and expenses | $\* |
| Total | $\* |

---

\* To be filed by amendment.

**Item 14. Indemnification of Directors and Officers.**

Section 7-108-402 of the Colorado Business Corporation Act (the "CBCA") provides, generally, that the articles of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director, except that any such provision shall not eliminate or limit the liability of a director for (i) any breach of the director's duty of loyalty to the corporation or its shareholders, (ii) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) acts specified in Section 7-108-403 of the CBCA, or (iv) any transaction from which the director directly or indirectly derived an improper personal benefit.

Section 7-109-102(1) of the CBCA permits indemnification of a director of a Colorado corporation, in the case of a third party action, if the director (a) conducted himself or herself in good faith, (b) reasonably believed that (i) in the case of conduct in his or her official capacity, his or her conduct was in the corporation's best interest, or (ii) in all other cases, his or her conduct was not opposed to the corporation's best interest, and (c) in the case of any criminal proceeding, had no reasonable cause to believe that his conduct was unlawful. Section 7-109-103 further provides for mandatory indemnification of directors and officers who are successful on the merits or otherwise in litigation.

Section 7-109-102(4) of the CBCA limits the indemnification that a corporation may provide to its directors in two key respects. A corporation may not indemnify a director in a derivative action in which the director is held liable to the corporation, or in any proceeding in which the director is held liable on the basis of his improper receipt of a personal benefit. Sections 7-109-104 of the CBCA permits a corporation to advance expenses to a director, and Section 7-109-107(1)(c) of the CBCA permits a corporation to indemnify and advance litigation expenses to officers, employees and agents who are not directors to a greater extent than directors if consistent with law and provided for by the bylaws, a resolution of directors or shareholders, or a contract between the corporation and the officer, employee or agent.

Our bylaws include provisions that require the company to indemnify our directors or officers against monetary damages for actions taken as a director or officer of our Company. We are also expressly authorized to carry directors' and officers' insurance to protect our directors, officers, employees and agents for certain liabilities. Our articles of incorporation do not contain any limiting language regarding director immunity from liability.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed hereby in the Securities Act and we will be governed by the final adjudication of such issue.

**Item 15. Recent Sales of Unregistered Securities.**

In the three years preceding the filing of this registration statement, the Company has sold the following securities that were not registered under the Securities Act:

On May 12, 2023, the Company entered into a securities purchase agreement with an accredited investor for a private placement of the Company's common stock, Pre-Funded Warrants, each exercisable to purchase one share of common stock, and warrants, each exercisable to purchase one share of common stock. Pursuant to the purchase agreement, the Company sold (i) 1,225 shares of its common stock, (ii) warrants to purchase up to 5,952 shares of common stock, and (iii) 1,751 pre-funded warrants. Each share of common stock and accompanying two warrants were sold together at a combined offering price of $1,680, and each pre-funded warrant and accompanying two warrants were sold together at a combined offering price of $1,678. The pre-funded warrants were immediately exercisable, at a nominal exercise price of $2.00, and could be exercised at any time until all of the pre-funded warrants were exercised in full. The warrants were exercisable immediately for a period of five and half year and had an initial exercise price of $1,180 per share (subject to adjustment as set forth therein).

Aegis Capital Corp. acted as the placement agent in connection with the private placement and was paid a commission equal to 10% of the gross proceeds received by the Company, and a non-accountable expense allowance equal to 2% of the gross proceeds, and will receive 10% of the proceeds from any exercise of warrants, payable on exercise.

On March 4, 2024, the Company sold 100,000 shares of the Company's Series B Preferred Stock to the Company's Chief Executive Officer, Dr. Steve Slilaty, for $10,000.

On April 14, 2026, the Company issued 100,000 shares of common stock to David Natan, the Company's director, for services provided.

In connection with the foregoing, we relied upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended, for transactions not involving a public offering.

**Item 16. Exhibits and Financial Statement Schedules.**

**(a) Exhibits.**

---

| | |
|:---|:---|
| 3.1 | [Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1402328/000107997407000547/mountainwsb2ex31_10182007.htm) (2) |
| 3.2 | [Certificate of Amendment to Articles of Incorporation filed November 2, 2009](http://www.sec.gov/Archives/edgar/data/1402328/000101359609000030/exh3-3.htm) (3) |
| 3.3 | [Statement of Share and Equity Capital Exchange](http://www.sec.gov/Archives/edgar/data/1402328/000101359610000075/exh3-4.htm) (4) |
| 3.4 | [Articles of Amendment to Articles of Incorporation filed July 13, 2010](http://www.sec.gov/Archives/edgar/data/1402328/000101359610000075/exh3-5.htm) (4) |
| 3.5 | [Articles of Amendment to Articles of Incorporation filed May 27, 2015](http://www.sec.gov/Archives/edgar/data/1402328/000135448815002794/sbfm_ex35.htm) (5) |
| 3.6 | [Articles of Amendment to Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1402328/000165495420006915/sbfm_ex36.htm) (6) |
| 3.7 | [Articles of Amendment to Articles of Incorporation](http://www.sec.gov/Archives/edgar/data/1402328/000168316822000809/sunshine_ex0307.htm) (7) |
| 3.8 | [Articles of Amendment to Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1402328/000168316824002616/sunshine_ex0301.htm) (25) |
| 3.9 | [Articles of Amendment to Articles of Incorporation](https://www.sec.gov/Archives/edgar/data/1402328/000168316824005496/sunshine_ex0301.htm) (26) |
| 3.1 | [Certificate of Correction](https://www.sec.gov/Archives/edgar/data/1402328/000168316824007657/sunshine_ex0310.htm) (28) |
| 3.11 | [Bylaws](http://www.sec.gov/Archives/edgar/data/1402328/000107997407000547/mountainwsb2ex32_10182007.htm) (14) |
| 4.1 | [Description of Registrant's Securities](http://www.sec.gov/Archives/edgar/data/1402328/000168316822001788/sunshine_ex0401.htm) (16) |
| 5.1 | Opinion of Evans Case, LLP,\*\* |
| 5.2 | Opinion of Sichenzia Ross Ference Carmel LLP \*\* |
| 10.1 | [Patent Purchase Agreement with Advanomics Corporation](http://www.sec.gov/Archives/edgar/data/1402328/000135448815004592/sbfm_ex109.htm) (8) |
| 10.2 | [Second Patent Purchase Agreement with Advanomics Corporation](http://www.sec.gov/Archives/edgar/data/1402328/000135448815005669/sbfm_ex109.htm) (9) |
| 10.3 | [Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated October 8, 2016, including Secured Convertible Promissory Note](http://www.sec.gov/Archives/edgar/data/1402328/000165495416000160/sbfm_ex1010.htm) (10) |
| 10.4 | [Amendment No. 1 to Patent Purchase Agreement with Advanomics Corporation dated December 28, 2016, including Secured Convertible Promissory Note](http://www.sec.gov/Archives/edgar/data/1402328/000165495416000160/sbfm_ex1011.htm) (10) |
| 10.5 | [Form of Warrant, dated February 17, 2022](https://www.sec.gov/Archives/edgar/data/1402328/000168316822001090/sunshine_ex0401.htm) (1) |
| 10.6 | [Warrant Agent Agreement between the Company and Equiniti, dated February 17, 2022](http://www.sec.gov/Archives/edgar/data/1402328/000168316822001090/sunshine_ex1001.htm) (1) |
| 10.7 | [Sponsored Research Agreement, dated October 6, 2020, between the Company and the University of Georgia Research Foundation, Inc.](http://www.sec.gov/Archives/edgar/data/1402328/000168316822000418/sunshine_ex1007.htm) (11) \* |
| 10.8 | [Research Agreement between the Company and Arizona Board of Regents on behalf of the University of Arizona](http://www.sec.gov/Archives/edgar/data/1402328/000168316822001271/sunshine_ex1001.htm) (12) |
| 10.9 | [Form of Warrant, dated March 14, 2022](http://www.sec.gov/Archives/edgar/data/1402328/000168316822001654/sunshine_ex1003.htm) (15) |
| 10.1 | [Form of Amendment to Warrant, dated March 24, 2022](http://www.sec.gov/Archives/edgar/data/1402328/000168316822001920/sunshine_ex9901.htm) (17) |
| 10.11 | [Amended Employment Agreement, dated October 21, 2024 between Sunshine Biopharma Inc. and Dr. Steve Slilaty](http://www.sec.gov/Archives/edgar/data/1402328/000168316822002473/sunshine_ex1001.htm) (18) |
| 10.12 | [Employment Agreement, dated October 21, 2024, between the Company and Camille Sebaaly](https://www.sec.gov/Archives/edgar/data/1402328/000168316824007323/sunshine_ex1002.htm) (18) |
| 10.13 | [Share Purchase Agreement between Sunshine Biopharma Inc., Malek Chamoun and Nora Pharma Inc.](http://www.sec.gov/Archives/edgar/data/1402328/000168316822006971/sunshine_ex1001.htm) (19) |
| 10.14 | [License Agreement between the Company and the University of Arizona](http://www.sec.gov/Archives/edgar/data/1402328/000168316823001172/sunshine_ex1001.htm) (20) \* |
| 10.15 | [Amendment No. 1 to Warrant Agent Agreement, dated October 18, 2023](http://www.sec.gov/Archives/edgar/data/1402328/000168316823007302/sunshine_1001.htm) (21) |
| 10.16 | [2023 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1402328/000168316824000105/sunshine_ex0401.htm) (22) |
| 10.17 | [Form of Series B Warrant](https://www.sec.gov/Archives/edgar/data/1402328/000168316824001009/sunshine_ex1003.htm) (23) |
| 10.18 | [Placement Agent Agreement, dated April 2, 2025](https://www.sec.gov/Archives/edgar/data/1402328/000168316825002245/sunshine_ex1002.htm) (27) |
| 10.19 | [Engagement Agreement, dated April 20, 2026](sunshine_ex1019.htm) |
| 10.2 | Form of Pre-Funded Warrant for this offering \*\* |
| 10.21 | Form of Series C Warrant for this offering \*\* |
| 10.22 | Form of Securities Purchase Agreement for this offering \*\* |
| 14.1 | [Code of Ethics](http://www.sec.gov/Archives/edgar/data/1402328/000165495420004731/sbfm_ex14.htm) (13) |
| 21.0 | [Subsidiaries](http://www.sec.gov/Archives/edgar/data/1402328/000168316823002128/sunshine_ex2100.htm) (24) |
| 23.1 | Consent of Bush & Associates CPA LLC \*\* |

---

---

| | |
|:---|:---|
| 23.2 | Consent of M&K CPAS, PLLC \*\* |
| 23.3 | Consent of Evans Case, LLP (included in Exhibit 5.1) \*\* |
| 23.4 | Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.2) \*\* |
| 107 | Fee Table \*\* |
| EX-101 | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) |
| EX-104 | Cover Page Interactive Data File (formatted in iXBRL, and included in exhibit 101) |

---

_______________________

\* Portions of the exhibit have been omitted. <br> \*\* To be filed by amendment.

(1) Incorporated by reference to 8-K filed with the SEC on February 17, 2022

(2) Incorporated by reference to SB-2 filed with the SEC on October 19, 2007.

(3) Incorporated by reference to 8-K filed with the SEC on November 6, 2009.

(4) Incorporated by reference to 10-Q filed with the SEC on August 4, 2010.

(5) Incorporated by reference to 8-K filed with the SEC on June 1, 2015.

(6) Incorporated by reference to 8-K filed with the SEC on June 24, 2020.

(7) Incorporated by reference to 8-K filed February 9, 2022.

(8) Incorporated by reference to 8-K filed with the SEC on October 9, 2015.

(9) Incorporated by reference to 8-K filed with the SEC on December 28, 2015.

(10) Incorporated by reference to 8-K filed with the SEC on March 14, 2016.

(11) Incorporated by reference to S-1/A filed with the SEC on January 24, 2022.

(12) Incorporated by reference to 8-K filed with the SEC on February 25, 2022.

(13) Incorporated by reference to 10-K filed with the SEC on May 1, 2020.

(14) Incorporated by reference to 8-K filed with the SEC on April 19, 2023.

(15) Incorporated by reference to 8-K filed with the SEC on March 15, 2022.

(16) Incorporated by reference to 10-K filed with the SEC on March 21, 2022.

(17) Incorporated by reference to 8-K filed with the SEC on March 24, 2022.

(18) Incorporated by reference to 8-K filed with the SEC on October 23, 2024.

(19) Incorporated by reference to 8-K filed with the SEC on October 20, 2022.

(20) Incorporated by reference to 8-K filed with the SEC on February 28, 2023.

(21) Incorporated by reference to 8-K filed with the SEC on October 20, 2023.

(22) Incorporated by reference to S-8 filed with the SEC on January 8, 2024.

(23) Incorporated by reference to 8-K filed with the SEC on February 15, 2024.

(24) Incorporated by reference to 10-K filed with the SEC on March 28, 2024.

(25) Incorporated by reference to 8-K filed with the SEC on April 23, 2024.

(26) Incorporated by reference to 8-K filed with the SEC on August 12, 2024.

(27) Incorporated by reference to 8-K filed with the SEC on April 3, 2025.

(28) Incorporated by reference to S-1/A filed with the SEC on November 6, 2024.

\* Filed herewith. <br> \*\* To be filed by amendment.

**(b) Financial statement schedules**

Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.

**Item 17. Undertakings**

The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

The undersigned registrant hereby undertakes that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

2. For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fort Lauderdale, State of Florida, on April __, 2026.

---

| | |
|:---|:---|
| **Sunshine Biopharma Inc.** | **Sunshine Biopharma Inc.** |
| By: |  |
| Name: | Dr. Steve N. Slilaty |
| Title: | Chief Executive Officer |
|  | (Principal Executive Officer) |

---

Each person whose signature appears below constitutes and appoints Dr. Steve N. Slilaty, his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution for him and in his name, place and stead, and in any and all capacities, to sign for him and in him name in the capacities indicated below any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
|  | Chief Executive Officer and Director | April __, 2026 |
| Dr. Steve N. Slilaty | (Principal Executive Officer) |  |
|  | Chief Financial Officer and Director | April __, 2026 |
| Camille Sebaaly | (Principal Financial and Accounting Officer) |  |
|  | Director | April __, 2026 |
| David Natan |  |  |
|  | Director | April __, 2026 |
| Dr. Andrew Keller |  |  |
|  | Director | April __, 2026 |
| Dr. Rabi Kiderchah |  |  |

---

## Exhibit 10.19

**Exhibit 10.19**

![](aegis_logo.jpg)

April 20, 2026

**<u>PERSONAL AND CONFIDENTIAL</u>**

Dr. Steve N. Slilaty, Chief Executive Officer

Sunshine Biopharma Inc.

333 Las Olas Way<br> CU4 Suite 433<br> Fort Lauderdale, FL 33301<br> United States

---

| | |
|:---|:---|
| **Re:** | **<u>SBFM \| Best Efforts Secondary Offering \| Engagement Letter</u>** |

---

Dear Dr. Slilaty:

The purpose of this engagement letter is to outline our agreement pursuant to which Aegis Capital Corp. ("**<u>Aegis</u>**") will act as the placement agent on a "best efforts" basis in connection with the proposed Best Efforts Secondary Offering (the "**<u>Placement</u>**") by Sunshine Biopharma, Inc. (collectively, with its subsidiaries and affiliates, the "**<u>Company</u>**") of its shares of Common Stock and/or other securities convertible into or exercisable for common stock (the "**<u>Securities</u>**"). This engagement letter sets forth certain conditions and assumptions upon which the Placement is premised. The Company expressly acknowledges and agrees that Aegis's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Aegis to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Aegis with respect to securing any other financing on behalf of the Company. Except as expressly provided herein, this engagement letter is not intended to be a binding legal document, as the binding agreement on the matters relating to the Placement will be embodied in the Securities Purchase Agreement (as defined below). The Company confirms that entry into this engagement letter and completion of the Placement with Aegis will not breach or otherwise violate the Company's obligations to any other party or require any payments to such other party. For the sake of clarity, such obligations may include but not be limited to obligations under an engagement letter, placement agency agreement, underwriting agreement, advisory agreement, right of first refusal, tail fee obligation or other agreement.

The terms of our agreement in principle are as follows:

1.  **<u>Engagement</u>** . The Company hereby engages Aegis, for the period beginning on the date hereof
and ending two (2) months thereafter or upon the completion of the Placement, whichever is sooner (the "  **<u>Engagement Period</u>** "),
to act as the Company's exclusive investment bank in connection with the proposed Placement. During the Engagement Period or until
the consummation of the Placement, and as long as Aegis is proceeding in good faith with preparations for the Placement, the Company agrees
not to solicit, negotiate with or enter into any agreement with any other source of financing (whether equity, debt or otherwise), any
underwriter, potential underwriter, placement agent, financial advisor, investment banking firm or any other person or entity in connection
with an offering of the Company's debt or equity securities or any other financing by the Company. Aegis will use its reasonable
"best efforts" to solicit offers to purchase the Securities from the Company on the terms, and subject to the conditions,
set forth in the Prospectus (as defined below). Aegis shall use commercially reasonable efforts to assist the Company in obtaining performance
by each Purchaser (as defined below) whose offer to purchase Securities has been solicited by Aegis, but Aegis shall not, except as otherwise
provided in this Agreement, be obligated to disclose the identity of any potential purchaser or have any liability to the Company in the
event any such purchase is not consummated for any reason. The Company acknowledges that under no circumstances will Aegis be obligated
to underwrite or purchase any Securities for its own account and, in soliciting purchases of the Securities, Aegis shall act solely as
an agent of the Company. The services provided pursuant to this engagement letter shall be on an "agency" basis and not on
a "principal" basis.

**1345 Avenue of the Americas** **· New York, New York · 10105**

**(212) 813-1010** **· Fax (212) 813-1047 · Member FINRA, SIPC**

![](aegis_image002.jpg)

2.  **<u>The Placement</u>** . The Placement is expected to consist of a sale of up to approximately $6.0
million of the Company's Securities. The structure and pricing of the Placement will be mutually agreed upon by the Company and
the investors thereto. Aegis will act as placement agent for the Placement subject to, among other matters referred to herein and additional
customary conditions, completion of Aegis's due diligence examination of the Company and its affiliates, listing approval by the
Nasdaq Capital Market ("  **<u>Exchange</u>**") of the Securities to be issued, and the execution of a definitive Securities
Purchase Agreement in connection with the Placement (the "  **<u>Securities Purchase Agreement</u>** "). The actual size of
the Placement, the precise number and type of Securities to be offered by the Company and the offering price will be the subject of continuing
negotiations between the Company and the investors thereto. In connection with the entry into the Securities Purchase Agreement, the Company
(i) will meet with Aegis and its representatives to discuss such due diligence matters and to provide such documents as Aegis may require;
(ii) will not file with the Commission any document regarding the Placement without the prior approval of Aegis and its counsel; (iii)
will deliver to Aegis and the investors in the Placement such legal and accounting opinions and letters (including, without limitation,
accounting comfort letters, legal opinions, negative assurance letters, good standing certificates and officers' and secretary certificates)
as Aegis may require, all in form and substance acceptable to Aegis and (iv) will ensure that Aegis is a third party beneficiary of all
representations, warranties, covenants, closing conditions and deliverables in connection with the Placement.

3.  **<u>Placement Compensation</u>** . The placement commission will be 7.0% for the Placement and a non-accountable
expense allowance equal to 2.0% of the Placement.

4.  **<u>Registration Statement</u>** . To the extent the Company decides to proceed with the Placement,
the Company will, as soon as practicable, prepare and file with the Securities and Exchange Commission (the "  **<u>Commission</u>** ")
a Registration Statement on Form S-1 (the "  **<u>Registration Statement</u>**") under the Securities Act of 1933, as amended
(the "  **<u>Securities Act</u>**") and a prospectus included therein (the "  **<u>Prospectus</u>**") covering
the Securities to be offered and sold in the Placement. The Registration Statement (including the Prospectus therein), and all amendments
and supplements thereto, will be in form reasonably satisfactory to Aegis and counsel to Aegis. Other than any information provided by
Aegis in writing specifically for inclusion in the Registration Statement or the Prospectus, the Company will be solely responsible for
the contents of its Registration Statement and Prospectus and any and all other written or oral communications provided by or on behalf
of the Company to any actual or prospective investor of the Securities, and the Company represents and warrants that such materials and
such other communications will not, as of the date of the offer or sale of the Securities, contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. If at any time prior to the completion of the offer and sale of the Securities
an event occurs that would cause the Registration Statement or Prospectus (as supplemented or amended) to contain an untrue statement
of a material fact or to omit to state a material fact necessary in order to make the statements therein, in light of the circumstances
under which they were made, not misleading, the Company will notify Aegis immediately of such event and Aegis will suspend solicitations
of the prospective purchasers of the Securities until such time as the Company shall prepare a supplement or amendment to the Registration
Statement or Prospectus that corrects such statement or omission. The Registration Statement will include as an exhibit a proposed form
of Placement Agent Agreement (which may be incorporated into such Registration Statement by reference). The final Placement Agent Agreement
will be in form satisfactory to the Company and Aegis and will include indemnification provisions and other terms and conditions customarily
found in such agreements.

5.  **<u>Lock-Ups</u>** . In connection with the Placement, the Company's directors, executive officers,
employees and shareholders holding at least ten percent (10%) of the outstanding common stock will enter into customary "lock-up"
agreements in favor of the Placement Agent for a period of ninety (90) days after the Closing of the Placement (the "  **<u>Lock-Up Period</u>** "); provided, however, that any sales by parties to the lock-ups shall be subject to the lock-up agreements and provided
further, that none of such common stock shall be saleable in the public market until the expiration of the Lock-Up Period.

![](aegis_image002.jpg)

6.  **<u>Company Standstill</u>** . In connection with the Placement, without the prior written consent
of the investors, the Company will not, for a period of ninety (90) days after the Closing of the Placement (the "  **<u>Standstill Period</u>** "), (a) offer, sell, issue, or otherwise transfer or dispose of, directly or indirectly, any equity of the Company
or any securities convertible into or exercisable or exchangeable for equity of the Company; (b) file or caused to be filed any registration
statement with the Commission relating to the offering of any equity of the Company or any securities convertible into or exercisable
or exchangeable for equity of the Company; or (c) enter into any agreement or announce the intention to effect any of the actions described
in subsections (a) or (b) hereof (all of such matters, the "  **<u>Standstill Restrictions</u>** "). So long as none of such
equity securities shall be saleable in the public market until the expiration of the Standstill Period, the following matters shall not
be prohibited by the Standstill Restrictions: (i) the adoption of an equity incentive plan and the grant of awards or equity pursuant
to any equity incentive plan, and the filing of a registration statement on Form S-8; (ii) securities issued pursuant to agreements, options,
restricted share units or convertible securities existing as of the date hereof provided the terms are not modified; and (iii) securities
issued pursuant to acquisitions or strategic transactions (whether by merger, consolidation, purchase of equity, purchase of assets, reorganization
or otherwise) approved by a majority of the disinterested directors of the Company, provided that such securities are issued as "restricted
securities" (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement
in connection therewith during the Standstill Period, and provided that any such issuance shall only be to a person or entity (or to the
equityholders of an entity) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic
with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall
not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
primary business is investing in securities. In no event should any equity transaction during the Standstill Period result in the sale
of equity at an offering price to the public less than that of the Placement referred herein.

7.  **<u>Expenses</u>** . The Company will be responsible for and will pay all expenses relating to the
Placement, including, without limitation, (a) all filing fees and expenses relating to the registration of the Securities with the Commission;
(b) all FINRA Public Offering filing fees; (c) all fees and expenses relating to the listing of the Company's equity or equity-linked
securities on an Exchange; (d) all fees, expenses and disbursements relating to the registration or qualification of the Securities under
the "blue sky" securities laws of such states and other jurisdictions as Aegis may reasonably designate (including, without
limitation, all filing and registration fees, and the reasonable fees and disbursements of the Company's "blue sky"
counsel, which will be Aegis's counsel) unless such filings are not required in connection with the Company's proposed Exchange
listing; (e) any fees for counsel to lead investors in the Placement; (f) all fees, expenses and disbursements relating to the registration,
qualification or exemption of the Securities under the securities laws of such foreign jurisdictions as Aegis may reasonably designate;
(g) the costs of all mailing and printing of the Placement documents; (h) transfer and/or stamp taxes, if any, payable upon the transfer
of Securities from the Company to Aegis; (i) the fees and expenses of the Company's accountants; and (j) $100,000 for reasonable
legal fees and disbursements for Aegis's counsel.

8.  **<u>Reserved.</u>** 

9.  **<u>Survival</u>** . Except as provided in Sections 3, 7, 10, 11, 12, 13, 14, 15 and 16 hereof (which
Sections are intended to be <u>legally</u> binding and enforceable on and against the Company and Aegis), the exclusivity language in
Section 1 and this Section, this engagement letter is not intended to be a binding legal document nor a legal commitment on the part of
Aegis to provide any financing to the Company, as the agreement between the parties hereto on these matters will be embodied in the Placement
Agent Agreement.

10.  **<u>Termination</u>** . Notwithstanding anything to the contrary contained herein, the Company agrees
that the provisions relating to the payment of fees, reimbursement of expenses, indemnification and contribution, equitable remedies,
confidentiality, conflicts, independent contractor and waiver of the right to trial by jury will survive any termination or expiration
of this engagement letter. Notwithstanding anything to the contrary contained herein, the Company has the right to terminate the engagement
letter for cause in compliance with FINRA Rule 5110(g)(5)(B)(i). Notwithstanding anything to the contrary contained in this engagement
letter, in the event that no Placement is completed for any reason whatsoever during the Engagement Period, the Company shall be obligated
to pay to Aegis its reasonable actual and accountable out-of-pocket expenses related to the Placement (including the fees and disbursements
of Placement Agent's legal counsel) and if applicable, for electronic road show service used in connection with the Placement up
to an aggregate of $100,000. During the engagement hereunder: (i) the Company will not, and will not permit its representatives to, other
than in coordination with Aegis, contact or solicit institutions, corporations or other entities or individuals as potential purchasers
of the Securities and (ii) the Company will not pursue any financing transaction which would be in lieu of the Placement. Furthermore,
the Company agrees that during Aegis's engagement hereunder, all inquiries from prospective investors will be referred to Aegis.

![](aegis_image002.jpg)

11.  **<u>Publicity</u>** . The Company agrees that it will not issue press releases or engage in any other
publicity, without Aegis's prior written consent, commencing on the date hereof and continuing until the final Closing of the Placement.

12.  **<u>Information</u>** . During the Engagement Period or until the Closing, the Company agrees to cooperate
with Aegis and to furnish, or cause to be furnished, to Aegis, any and all information and data concerning the Company, and the Placement
that Aegis deems appropriate (the "  **<u>Information</u>** "). The Company will provide Aegis reasonable access during normal
business hours from and after the date of execution of this engagement letter until the Closing to all of the Company's assets,
properties, books, contracts, commitments and records and to the Company's officers, directors, employees, appraisers, independent
accountants, legal counsel and other consultants and advisors. Except as contemplated by the terms hereof or as required by applicable
law, Aegis will keep strictly confidential all non-public Information concerning the Company provided to Aegis. No obligation of confidentiality
will apply to Information that: (a) is in the public domain as of the date hereof or hereafter enters the public domain without a breach
by Aegis, (b) was known or became known by Aegis prior to the Company's disclosure thereof to Aegis as demonstrated by the existence
of its written records, (c) becomes known to Aegis from a source other than the Company which information is not provided by the breach
of an obligation of confidentiality owed to the Company, (d) is disclosed by the Company to a third party without restrictions on its
disclosure or (e) is independently developed by Aegis as demonstrated by its written records. For the avoidance of doubt, except as otherwise
provided herein, all information which is not publicly available relating to the Company's proprietary technology is proprietary
and confidential.

13.  **<u>No Third Party Beneficiaries; No Fiduciary Obligations</u>** . This engagement letter does not
create, and shall not be construed as creating, rights enforceable by any person or entity not a party hereto, except those entitled hereto
by virtue of the indemnification provisions hereof. The Company acknowledges and agrees that: (i) Aegis is not and shall not be construed
as a fiduciary of the Company and shall have no duties or liabilities to the equity holders or the creditors of the Company or any other
person or entity by virtue of this engagement letter or the retention of Aegis hereunder, all of which are hereby expressly waived; and
(ii) Aegis is a full service securities firm engaged in a wide range of businesses and from time to time, in the ordinary course of its
business, Aegis or its affiliates may hold long or short positions and trade or otherwise effect transactions for its own account or the
account of its customers in debt or equity securities or loans of the companies which may be the subject of the transactions contemplated
by this engagement letter. During the course of Aegis's engagement with the Company, Aegis may have in its possession material,
non-public information regarding other companies that could potentially be relevant to the Company or the transactions contemplated herein
but which cannot be shared due to an obligation of confidence to such other companies.

14.  **<u>Indemnification, Advancement & Contribution</u>** .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.1. **<u>Indemnification</u>**. The Company agrees to indemnify and hold harmless Aegis, its affiliates and each person controlling Aegis (within the meaning of Section 15 of the Securities Act), and the directors, officers, agents and employees of Aegis, its affiliates and each such controlling person (Aegis, and each such entity or person hereafter is referred to as an "**<u>Indemnified Person</u>**") from and against any losses, claims, damages, judgments, assessments, costs and other liabilities (collectively, the "**<u>Liabilities</u>**"), and shall reimburse each Indemnified Person for all fees and expenses (including the reasonable fees and expenses of counsel for the Indemnified Persons) (collectively, the "**<u>Expenses</u>**") and agrees to advance payment of such Expenses as they are incurred by an Indemnified Person in investigating, preparing, pursuing or defending any actions, whether or not any Indemnified Person is a party thereto, arising out of or based upon (i) any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration Statement, Prospectus or any other offering documents (as from time to time each may be amended and supplemented), (B) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the Placement, including any "road show" or investor presentations made to investors by the Company (whether in person or electronically), or (C) any application or other document or written communication (collectively called "application") executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Securities under the securities laws thereof or to file for an exemption from such requirement or filed with the Commission, any state securities commission or agency, any national securities exchange; or (ii) the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement or omission was made in reliance upon, and in conformity with, information provided to the Company by Aegis in writing specifically for use in the Registration Statement, Prospectus or any other offering documents with respect which or resulting from conduct by Aegis or another Indemnified Party, as to which Aegis shall indemnify and hold harmless the Company, its officers, directors and controlling parties in the manner set forth in this Section 14. The Company also agrees to reimburse and advance each Indemnified Person for all Expenses as they are incurred in connection with such Indemnified Person's enforcement of his or its rights under this Section 14.

![](aegis_image002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.2. **<u>Procedure</u>**. Upon receipt by an Indemnified Person of actual notice of an action against such Indemnified Person with respect to which indemnity may reasonably be expected to be sought under this Section 14, such Indemnified Person shall promptly notify the Company in writing; provided that failure by any Indemnified Person so to notify the Company shall not relieve the Company from any obligation or liability which the Company may have on account of this Section 14 or otherwise to such Indemnified Person. The Company shall, if requested by Aegis, assume the defense of any such action (including the employment of counsel designated by Aegis and reasonably satisfactory to the Company). Any Indemnified Person shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company has failed promptly to assume the defense and employ separate counsel reasonably acceptable to Aegis for the benefit of Aegis and the other Indemnified Persons or (ii) such Indemnified Person shall have been advised that in the opinion of counsel that there is an actual or potential conflict of interest that prevents (or makes it imprudent for) the counsel designated by and engaged by the Company for the purpose of representing the Indemnified Person, to represent both such Indemnified Person and any other person represented or proposed to be represented by such counsel, in which event the Company shall pay the reasonable fees and expenses of one counsel, plus local counsel, for all Indemnified Parties, which counsel shall, if Aegis is a defendant, be designated by Aegis. The Company shall not be liable for any settlement of any action effected without its written consent (which shall not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of Aegis, settle, compromise or consent to the entry of any judgment in or otherwise seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution may be sought hereunder (whether or not such Indemnified Person is a party thereto) unless such settlement, compromise, consent or termination (i) includes an unconditional release of each Indemnified Person, acceptable to such Indemnified Party, from all Liabilities arising out of such action for which indemnification or contribution may be sought hereunder and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any Indemnified Person. The advancement, reimbursement, indemnification and contribution obligations of the Company required hereby shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as every Liability and Expense is incurred and is due and payable, and in such amounts as fully satisfy each and every Liability and Expense as it is incurred (and in no event later than 30 Calendar Days following the date of any invoice therefore).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.3. **<u>Contribution</u>**. In the event that a court of competent jurisdiction makes a finding, final beyond right of review, that indemnity is unavailable to an Indemnified Person, the Company shall contribute to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect (i) the relative benefits to the Company, on the one hand, and to Aegis and any other Indemnified Person, on the other hand, of the matters contemplated by this Section 14 or (ii) if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only such relative benefits but also the relative fault of the Company, on the one hand, and Aegis and any other Indemnified Person, on the other hand, in connection with the matters as to which such Liabilities or Expenses relate, as well as any other relevant equitable considerations; provided that in no event shall the Company contribute less than the amount necessary to ensure that all Indemnified Persons, in the aggregate, are not liable for any Liabilities and Expenses in excess of the amount of commissions and non-accountable expense allowance actually received by Aegis in the Placement. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or Aegis on the other and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and Aegis agree that it would not be just and equitable if contributions pursuant to this subsection 14.3 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in this subsection 14.3. For purposes of this paragraph, the relative benefits to the Company, on the one hand, and to Aegis on the other hand, of the matters contemplated by this Section 14 shall be deemed to be in the same proportion as: (a) the total value received by the Company in the Placement, whether or not such Placement is consummated, bears to (b) the commissions paid to Aegis under the Placement Agent Agreement. Notwithstanding the above, no person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the Securities Act shall be entitled to contribution from a party who was not guilty of fraudulent misrepresentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.4. **<u>Limitation</u>**. The Company also agrees that no Indemnified Person shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with advice or services rendered or to be rendered by any Indemnified Person pursuant to this engagement letter, the transactions contemplated thereby or any Indemnified Person's actions or inactions in connection with any such advice, services or transactions, except to the extent that a court of competent jurisdiction has made a finding that Liabilities (and related Expenses) of the Company have resulted exclusively from such Indemnified Person's gross negligence or willful misconduct in connection with any such advice, actions, inactions or services.

![](aegis_image002.jpg)

15.  **<u>Equitable Remedies</u>** . Each party to this engagement letter acknowledges and agrees that (a)
a breach or threatened breach by the Company of any of its obligations under Section 8 or the exclusivity provisions of Section 1 would
give rise to irreparable harm to Aegis for which monetary damages would not be an adequate remedy and (b) if a breach or a threatened
breach by the Company of any such obligations occurs, Aegis will, in addition to any and all other rights and remedies that may be available
to such party at law, at equity, or otherwise in respect of such breach, be entitled to equitable relief, including a temporary restraining
order, an injunction, specific performance of the terms of Section 8 or the exclusivity provisions of Section 1, as applicable, and any
other relief that may be available from a court of competent jurisdiction, without any requirement to (i) post a bond or other security,
or (ii) prove actual damages or that monetary damages will not afford an adequate remedy. Each party to this engagement letter agrees
that such party shall not oppose or otherwise challenge the existence of irreparable harm, the appropriateness of equitable relief or
the entry by a court of competent jurisdiction of an order granting equitable relief, in either case, consistent with the terms of this
Section 15.

16.  **<u>Governing Law; Venue</u>** . This engagement letter will be deemed to have been made and delivered
in the State of New York, USA, and both the binding provisions of this engagement letter and the transactions contemplated hereby will
be governed as to validity, interpretation, construction, effect and in all other respects by the internal laws of the State of New York,
without regard to the conflict of laws principles thereof. Each of Aegis and the Company: (i) agrees that any legal suit, action or proceeding
arising out of or relating to this engagement letter and/or the transactions contemplated hereby will be instituted exclusively in the
courts located in the Borough of Manhattan, City of New York, County of New York, State of New York (ii) waives any objection which it
may have or hereafter to the venue of any such suit, action or proceeding, and (iii) irrevocably consents to the jurisdiction of the courts
located in the City of New York, County of New York and State of New York, in any such suit, action or proceeding. Each of Aegis and the
Company further agrees to accept and acknowledge service of any and all process which may be served in any such suit, action or proceeding
in such courts and agrees that service of process upon the Company mailed by certified mail to the Company's address will be deemed
in every respect effective service of process upon the Company, in any such suit, action or proceeding, and service of process upon Aegis
mailed by certified mail to Aegis's address will be deemed in every respect effective service process upon Aegis, in any such suit,
action or proceeding. Notwithstanding any provision of this engagement letter to the contrary, the Company agrees that neither Aegis nor
its affiliates, and the respective officers, directors, employees, agents and representatives of Aegis, its affiliates and each other
person, if any, controlling Aegis or any of its affiliates, will have any liability (whether direct or indirect, in contract or tort or
otherwise) to the Company for or in connection with the engagement and transaction described herein except for any such liability for
losses, claims, damages or liabilities incurred by the Company that are finally judicially determined to have resulted from the bad faith
or gross negligence of such individuals or entities. Aegis will act under this engagement letter as an independent contractor with duties
to the Company.

17.  **<u>Miscellaneous</u>** . The Company represents and warrants that it has all required power and authority
to enter into and carry out the terms and provisions of this engagement letter and the execution, delivery and performance of this engagement
letter does not breach or conflict with any agreement, document or instrument to which it is a party or bound. The binding provisions
of this engagement letter are legally binding upon and inure to the benefit of both the Company and Aegis and their respective assigns,
successors, and legal representatives. If any provision of this engagement letter is determined to be invalid or unenforceable in any
respect, such determination will not affect such provision in any other respect, and the remainder of the engagement letter shall remain
in full force and effect. This engagement letter may be executed in counterparts (including electronic counterparts), each of which shall
be deemed an original but all of which together shall constitute one and the same instrument. The undersigned hereby consents to receipt
of this engagement letter in electronic form and understands and agrees that this engagement letter may be signed electronically. Signatures
to this engagement letter transmitted in electronic form will have the same effect as physical delivery of a paper document bearing the
original signature, and if any signature is delivered electronically evidencing an intent to sign this engagement letter, such electronic
mail or other electronic transmission shall create a valid and binding obligation of the undersigned with the same force and effect as
if such signature were an original. Execution and delivery of this engagement letter by electronic mail or other electronic transmission
is legal, valid and binding for all purposes.

If you are in agreement with the foregoing, please sign and return to us one copy of this engagement letter. This engagement letter may be executed in counterparts (including facsimile or .pdf counterparts), each of which shall be deemed an original but all of which together shall constitute one and the same instrument.

*[Signature Page of SBFM Best Efforts Secondary Offering Engagement Letter Follows]*

![](aegis_image002.jpg)

*[Signature Page of SBFM Best Efforts Secondary Offering Engagement Letter]*

Very truly yours,<br>Aegis Capital Corp.<br>By: <u>/s/ Robert Eide</u> <br> Name: Robert Eide<br> Title: Chief Executive Officer<br>

**AGREED AND ACCEPTED**:

The foregoing accurately sets forth our understanding and agreement with respect to the matters set forth herein.

**Sunshine Biopharma Inc.**

---

| | |
|:---|:---|
| By: | <u>/s/ Steve N. Slilaty</u> |
| Name: | Steve N. Slilaty |
| Title: | Chief Executive Officer |

---